Saturday, 4 January 2020

Daratumumab involved in risk of reactivation of hepatitis B virus

The Medicines and Healthcare Products Regulatory Agency (MHRA) London has announced that the product information for daratumumab will be updated to include the risk of reactivation of hepatitis B virus (HBV).



source https://www.pharmatutor.org/pharma-news/2020/daratumumab-involved-in-risk-of-reactivation-of-hepatitis-b-virus
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Pharmaceutical Industry and pharma / Life Sciences institute openings 2025

  Intas Pharma Walk in Drive for M.Pharm, B.Pharm | Multiple Posts M.Pharma / B.Pharma. Injectable/Parenteral/Sterile - Aseptic, Manufacturi...